Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sophie Vermond"'
Autor:
Gemma Moiset, Sophie Vermond, Monique Hazenoot, Rene McLaughlin, Sabrina de Munnik, Marco Guadagnoli, Sanne Holt, Marijn Vlaming
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d87669392ddd46b18ce37510d23d849f
Autor:
Gemma Moiset, Sophie Vermond, Monique Hazenoot, Rene McLaughlin, Sabrina de Munnik, Marco Guadagnoli, Marijn Vlaming, Sann Holt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ea383c9993774934b82c985557612dba
Autor:
Bin Xue, Sophie Vermond, Ulrike Herbrand, David Harris, Gemma Moiset, Kolin Hribar, Julia Schuler
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b47fb6bf0a8eb6da9890ebfbc2725a81
https://doi.org/10.1136/jitc-2022-sitc2022.0299
https://doi.org/10.1136/jitc-2022-sitc2022.0299
Autor:
Sophie Vermond, Benita Quist, Monique Hazenoot, Rene McLaughlin, David Cobeta Lopez, Namrata Jayanth, Folkert Verkaar, Omar Aziz, Maria LH Vlaming, Sabrina de Munnik, Gemma Moiset
Publikováno v:
Cancer Research. 83:4058-4058
Engineered T cell therapies such as Chimeric Antigen Receptor (CAR) T cells and T cell receptor (TCR)-engineered T cells have emerged as a promising cancer therapy. To date, four anti-CD19 CAR-T and two anti-BCMA CAR-T products have been approved by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0214e862d09395726f28b1f691e7b6fd
https://doi.org/10.1158/1538-7445.am2023-4058
https://doi.org/10.1158/1538-7445.am2023-4058
Autor:
Marco Guadagnoli, Monique Hazenoot, Gemma Moiset, Sann Holt, Sophie Vermond, Sabrina de Munnik, Rene McLaughlin, Marijn Vlaming
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCell therapies such as Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor (TCR) T cells are immune-therapeutic approaches showing great momentum in research and the clinic. To date, four anti-CD19 CAR-T products and one anti-BCMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45983a689c0afa5573d6650161c84f87
https://doaj.org/article/ea383c9993774934b82c985557612dba
https://doaj.org/article/ea383c9993774934b82c985557612dba
Autor:
Sophie Vermond, Benita Quist, Sabrina de Munnik, Monique Hazenoot, Madalina Avramescu, Rene McLaughlin, Gemma Moiset, Marijn Vlaming
Publikováno v:
Cancer Research. 82:5576-5576
Engineered T cell therapies such as Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor (TCR) T cells have emerged as a promising cancer therapy. To date, four anti-CD19 CAR-T and one anti-BCMA CAR-T products have been approved by the FDA f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a55a5aef970f4c64fdc5781a71b8b2a
https://doi.org/10.1158/1538-7445.am2022-5576
https://doi.org/10.1158/1538-7445.am2022-5576
Autor:
Eva Oswald, Gemma Moiset, Kanstantsin Lashuk, Sophie Vermond, Monique Hazenoot, Julia Schüler
Publikováno v:
Cancer Research. 82:574-574
The advent of anti-HER2 therapy has prominently prolonged the time of disease progression and survival for metastatic breast cancer patients, where a decent proportion is suffering from a HER2+ tumor. Beside classical approaches via antibodies agains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f067157c8c501210054d2201117c4e56
https://doi.org/10.1158/1538-7445.am2022-574
https://doi.org/10.1158/1538-7445.am2022-574
Publikováno v:
Cell and Gene Therapy Insights. :731-731
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::227ca74797f83acb8ac27f20e6bdcb34
https://doi.org/10.18609/cgti.2022.110
https://doi.org/10.18609/cgti.2022.110
Autor:
Gemma Moiset, Julia Schüler, Katharina Schaich, Kanstantsin Lashuk, Sophie Vermond, Sanne Holt, Monique Hazenoot, Eva Oswald
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A150-A150
BackgroundAlthough most breast cancer patients are treated these days with a curative intention, there are still many patients progressing to metastatic disease. The advent of anti-HER2 therapy has prominently prolonged the time of disease progressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50a5696048f4282819980b4d5e4b864c
https://doi.org/10.1136/jitc-2021-sitc2021.142
https://doi.org/10.1136/jitc-2021-sitc2021.142
Autor:
Sophie Vermond, Marijn Vlaming, Marco Guadagnoli, Rene McLaughlin, Monique Hazenoot, Sanne Holt
Publikováno v:
Cancer Research. 81:294-294
Cell therapies, such as Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) T cells, are some of the latest immune-therapeutic approaches, showing great momentum in research and now the clinic. Only recently, two anti-CD19-CAR-T products have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bbce262b7b213bd20bba0975adac8ac
https://doi.org/10.1158/1538-7445.am2021-294
https://doi.org/10.1158/1538-7445.am2021-294